CVM.US CEL-SCI Corp

Healthcare Biotechnology USA Stocks
1.28 USD
Close of Nov 13, 2026
0.8900 7.80
Market cap
USD 22.5M
P/E
-
P/B
1.91x
ROE
-202.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is CVM.US undervalued?

Graham number

The Graham number of CEL-SCI Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CEL-SCI Corp fundamental analysis

No fundamental analysis for CEL-SCI Corp yet.

CEL-SCI Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates t…

Full company profile